Clinical Research Directory
Browse clinical research sites, groups, and studies.
Lumateperone in the Treatment of Stuttering, Childhood Onset Fluency Disorder
Sponsor: CSTrials Inc.
Summary
The primary objective of this study is to evaluate the efficacy and tolerability of Lumateperone in reducing stuttering symptoms. The following scales and samples will be collected for clinical and functional outcomes. • MLGSSS • SSS • Stuttering Severity Instrument (SSI-IV) • PHQ-9 • Barnes Akathisia • SAS • AIMS • CGI-I • CGI-S
Official title: A Single-Center, Double-Blind, Placebo-Controlled, Study to Evaluate Lumateperone, Flexible Doses of 21mg or 42mg in Patients With Moderate to Severe Childhood Onset Fluency Disorder, Stuttering.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2026-04-18
Completion Date
2027-10-31
Last Updated
2026-07-29
Healthy Volunteers
No
Conditions
Interventions
Lumateperone (ITI-007)
This medication is a tablet that is taken once daily
Placebo Tablet or Capsule
Matching Placebo
Locations (1)
CSTrials
Costa Mesa, California, United States